Also, the potential of SLFN11 as a prognostic biomarker has been confirmed in hepatocellular [48], gastric [49], esophageal [50], and bladder [51] cancer, in the majority of which SLFN11 expression was examined by immunohistochemistry. This evidence concerns the gene SLFN11 and cancer.